Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. More Details
Adequate balance sheet and overvalued.
Share Price & News
How has Psychemedics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PMD's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PMD underperformed the US Healthcare industry which returned 16.7% over the past year.
Return vs Market: PMD underperformed the US Market which returned 12.7% over the past year.
Price Volatility Vs. Market
How volatile is Psychemedics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StWhat Does Psychemedics' (NASDAQ:PMD) CEO Pay Reveal?
3 months ago | Simply Wall StIs Psychemedics (NASDAQ:PMD) A Risky Investment?
4 months ago | Simply Wall StWhy You Should Like Psychemedics Corporation’s (NASDAQ:PMD) ROCE
Is Psychemedics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PMD's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PMD's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PMD is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.
PE vs Market: PMD is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PMD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PMD is good value based on its PB Ratio (1.8x) compared to the US Healthcare industry average (2.8x).
How is Psychemedics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Psychemedics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Psychemedics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Healthcare industry.
How has Psychemedics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PMD is currently unprofitable.
Growing Profit Margin: PMD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PMD is unprofitable, and losses have increased over the past 5 years at a rate of 7% per year.
Accelerating Growth: Unable to compare PMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PMD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (31.1%).
Return on Equity
High ROE: PMD has a negative Return on Equity (-14.81%), as it is currently unprofitable.
How is Psychemedics's financial position?
Financial Position Analysis
Short Term Liabilities: PMD's short term assets ($9.8M) exceed its short term liabilities ($3.3M).
Long Term Liabilities: PMD's short term assets ($9.8M) exceed its long term liabilities ($8.6M).
Debt to Equity History and Analysis
Debt Level: PMD's debt to equity ratio (32.1%) is considered satisfactory.
Reducing Debt: PMD's debt to equity ratio has reduced from 46.2% to 32.1% over the past 5 years.
Debt Coverage: PMD's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if PMD's interest payments on its debt are well covered by EBIT.
What is Psychemedics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PMD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PMD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: PMD is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Raymond Kubacki (75 yo)
Mr. Raymond C. Kubacki has been the President and Chief Executive Officer at Psychemedics Corp., since July 1991. Prior to joining Psychemedics Corp., Mr. Kubacki served as Vice President National Accounts ...
CEO Compensation Analysis
Compensation vs Market: Raymond's total compensation ($USD736.80K) is about average for companies of similar size in the US market ($USD601.89K).
Compensation vs Earnings: Raymond's compensation has been consistent with company performance over the past year.
|Executive Vice President||0.67yr||US$436.50k||0.0091% |
|Vice President of Laboratory Operations||21.67yrs||US$349.80k||0.39% |
|42.67yrs||no data||no data|
|42.67yrs||no data||no data|
|VP of Finance||9.33yrs||US$271.67k||0.22% |
|VP & General Counsel||4.08yrs||no data||no data|
|Secretary||no data||no data||no data|
Experienced Management: PMD's management team is seasoned and experienced (21.7 years average tenure).
|Independent Director||5yrs||US$118.08k||0.023% |
|Independent Director||21.67yrs||US$118.08k||0.57% |
|Independent Director||29.67yrs||US$334.28k||2.44% |
|Independent Director||17yrs||US$119.43k||0.92% |
Experienced Board: PMD's board of directors are seasoned and experienced ( 17 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Psychemedics Corporation's company bio, employee growth, exchange listings and data sources
- Name: Psychemedics Corporation
- Ticker: PMD
- Exchange: NasdaqCM
- Founded: 1986
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$24.927m
- Shares outstanding: 5.53m
- Website: https://www.psychemedics.com
Number of Employees
- Psychemedics Corporation
- 289 Great Road
- Suite 200
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PMD||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Jan 1987|
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening a ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/23 06:15|
|End of Day Share Price||2020/09/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.